Vorinostat can upregulate PLD1 expression through the PKCζ-Sp1 signaling axis, and co-treatment with the PLD1 inhibitor VU0155069 was reported to reverse resistance and further inhibit GBM cell invasion, angiogenesis, and self-renewal [274]. Here, SP1 is linked to glioblastoma.